key: cord-0920644-ytvehz0h
authors: Shovlin, Claire L; Vizcaychipi, Marcela P
title: Vascular inflammation and endothelial injury in SARS-CoV-2 infection: The overlooked regulatory cascades implicated by the ACE2 gene cluster
date: 2020-08-10
journal: QJM
DOI: 10.1093/qjmed/hcaa241
sha: 1c70c2775b874c5171d5d51466105af25140c96a
doc_id: 920644
cord_uid: ytvehz0h

COVID-19 has presented physicians with an unprecedented number of challenges and mortality. The basic question is why, in contrast to other “respiratory” viruses, SARS-CoV-2 infection can result in such multi-systemic, life-threatening complications and a severe pulmonary vasculopathy. It is widely known that SARS-CoV-2 uses membrane-bound angiotensin-converting enzyme 2 (ACE2) as a receptor, resulting in internalisation of the complex by the host cell. We discuss the evidence that failure to suppress coronaviral replication within 5 days results in sustained downregulation of ACE2 protein expression, and that ACE2 is under negative-feedback regulation. We then expose openly-available experimental repository data that demonstrate the gene for ACE2 lies in a novel cluster of interegulated genes on the X chromosome including PIR encoding pirin (quercetin 2,3-dioxygenase), and VEGFD encoding the predominantly lung-expressed vascular endothelial growth factor D. The five double-elite enhancer/promoters that are known to be operational, and shared read-through lncRNA transcripts, imply that ongoing SARS-CoV-2 infection will reduce host defences to reactive oxygen species, directly generate superoxide O(2) - and H(2)O(2) (a “ROS storm”), and impair pulmonary endothelial homeostasis. Published cellular responses to oxidative stress complete the loop to pathophysiology observed in severe COVID-19. Thus for patients who fail to rapidly suppress viral replication, the newly-appreciated ACE2 co-regulated cluster predicts delayed responses that would account for catastrophic deteriorations. We conclude that ACE2 homeostatic drives provide a unified understanding which should help optimise therapeutic approaches during the wait until safe, effective vaccines and antiviral therapies for SARS-CoV-2 are delivered.

On binding to ACE2, the SARS-CoV-2 Spike (S) envelope protein is cleaved to subunits S1 and S2 by host proteases. 9 Specific amino acids in the S1 C-terminal domain (CTD) and host ACE2 form a network of hydrogen-bond and salt bridge interactions resulting in internalization of the complex by the host cell. 9, 10 The SARS-CoV-2-ACE2 interactions are 4-fold stronger than between SARS-CoV and ACE2. 10 The kinetics of recycling ACE2 following viral-ACE2 complex internalisation are not yet reported for SARS-CoV-2, but those of a related human coronavirus, HCoV-NL63, were examined by Dijkman and colleagues in Rhesus monkey epithelial cells. 14 They demonstrated that cell surface expression of ACE2 starts to reduce 3 days post infection, becoming almost undetectable in infected cells from day 5 to the end of their study period, and therefore of unknown duration. 14 This is for an essential protein where strong evolutionary constraints have served to maintain physiological activity: The evidence is multifactorial, 11 and most compelling ACE2 is a "loss-of-function intolerant" gene with a very low frequency of null alleles, 15,16 particularly in males who only have a single copy due to its X-chromosome location. Transcription upregulation is observed within hours for many proteins sequestered in pathophysiological settings. [17] [18] [19] Specifically for ACE2, mRNA transcription is regulated by an unknown negative-feedback signal attributed to ACE2 activity. 20 Thus when ACE2 activity is reduced, homeostatic responses operate to restore the protein, apparently via upregulation of gene transcription. 20

Upregulation of gene transcription is enhanced by regulatory DNA sequences that modulate distant target gene expression, often by long-range physical chromosomal interactions. Several enhancers regulate ACE2 transcription in man, and two (GH0XJ015596 and GH0XJ01557) meet what are considered to be quite stringent GeneHancer definitions for 'double-elite' enhancer-promoter interactions. 21,22 These restrict 'elite' enhancer assignment to a candidate regulatory element derived from more than one experimental data source, and 'double elite' promoter-enhancer interactions to those meeting likelihood-based score thresholds using expression quantitative trait loci, again derived from multiple sources. 21 The ACE2 co-regulated cluster of genes

The region on the human X-chromosome that contains the ACE2 gene is illustrated in Figure 1A , and annotated by position on both human genome reference sequence "build 37" (GRCh37/hg19), and "build 38" (38/hg38). ACE2 is encoded by the reverse (-) strand, and is sited between CLTRN and PIR, which is adjacent to VEGF-D.

These genes, which encode proteins with better-known names and functions, share enhancers and other regulatory elements with ACE2 ( Figure 1B) . Homeostatic responses attempting to restore expression of cell surface ACE in the setting of ongoing SARS-CoV-2 viral replication predict upregulation and/or perturbation of these critical proteins, as discussed in the next section.

The ACE2 enhancers GH0XJ015596 and GH0XJ015579 have double-elite interactions (confirmed by Hi-C 23 and expression quantitative trait loci from GTEx version v6p 30 ), with the promoter of PIR which encodes quercetin 2,3-dioxygenase ("pirin"), and is near-ubiquitously expressed. 30 The substrate of pirin is quercetin (3,3',4'5,7-penthydroxyflavone), a flavonoid considered to be one of the most potent antioxidants of plant origin. 31,32 Quercetin was identified as a potential COVID-19 therapy by supercomputer modelling of the viral S-human ACE2 receptor interface, 33 and by genomics-guided tracing of SARS-CoV-2 targets. 34 Quercetin has electron-donating properties due to a phenolic hydroxyl group essential for scavenging free radicals such as superoxide anion O 2 ·and these antioxidant activities are the reasons cited for two randomised controlled trials in COVID-19 that are currently recruiting on www.clintrials.gov. 

The next "downstream" (3') gene is VEGFD ( Figure 1A ). There are double-elite interactions between three PIR locus-encoded enhancers (GH0XJ015492, GH0XJ015473, and GH0XJ015471) and the promoter of VEGFD. 21, 22 Additionally, there is a long PIR and VEGD read-through RNA transcript that will not produce full length protein (lnc-VEGFD-1, Figure 2 ): 22,26-29 Any change in lnc-VEGFD-1 transcription, including that mediated by the ACE2 locus-encoded enhancers interacting with the PIR promoter, would alter the balance between the read-through and VEGD protein-coding transcripts. This is also relevant to COVID-19 since VEGFD encodes vascular endothelial growth factor D which is predominantly expressed in the lungs, 30 modifies differentiation, proliferation and permeability of vascular and lymphatic endothelial cells, 44 is a therapeutic target for lymphangioleiomyomatosis, 45 and independently predicts all-cause mortality in patients with suspected or known coronary artery disease. 46

There are additional regulatory interactions between the ACE2-encoded enhancers and the preceding genes, CLTRN (also known as TMEMM27) and CA5B ( Figure 2B ). CLTRN encodes collectrin which has roles in renal proximal tubule amino acid transporter trafficking, insulin exocytosis, and neuropsychiatric stability. 47 CA5B which is on the (+) strand (Figure 2A) , encodes the mitochondrialexpressed carbonic anhydrase 5B, a metalloproteinase that generates bicarbonate for metabolic liver enzymes: defective hepatic bicarbonate production leads to biochemical findings 48 that could be relevant to the alkalosis observed in some COVID-19 patients.

Notably, none of the major proteins or other species encoded by the contiguous genes have been linked based on curated pathways, protein-interactions, or text mining databases from over 20 million PubMed publications (Supplementary Figure 3) .

The section above outlines how cellular homeostatic feedback loops, in the setting of a continued stimulus to upregulate ACE2 transcription in infected cells with severely depleted cell surface ACE2, 15 will lead to the COVID-19 reminiscent scenario outlined in Figure 2 .

This linking of experimentally validated data provides a compelling prediction of the delayed, lifethreatening features observed following SARS-CoV-2 infection. It depends on only one assumptionthat relatively normal host transcription will be in operation in some SARS-CoV-2 infected cells, some of the time. This seems a reasonable assumption based on evidence from other viruses: Many interfere with host transcription, for instance, H1N1 influenza (A/WSN/33) viral infection results in a transient host transcriptional shutdown, with host RNA polymerase II gene occupancy depleted genome-wide. 49 There has been no evidence to date for a similar pattern in coronaviruses, but they do have RNA-dependent RNA polymerases, and therefore might interfere with RNA transcription.

However, for H1N1 influenza (A/WSN/33), escape occurs after several hours, when the virus switches to replication mode. 50 Given the prolonged time-course for COVID-19 infection, it would seem reasonable to assume that relatively normal host transcription will be in operation in some to most infected cells.

In these unprecedented times, there are substantial existing resources of experimental biological data, currently residing unflagged in major repositories, and available for interrogation, informed by firsthand knowledge of human physiology and pathology in the setting of COVID-19. Off target consequences are predicted to increase PIR transcription, and thus impair reactive oxygen species (ROS) scavenging and increase ROS as described in the text. VEGFD consequences are expected to be pulmonary endothelial-specific, and additional cluster genes are not illustrated for clarity. known also as lncVEGFD-1.2 29 reads from PIR exon 2 to the 3' untranslated region of VEGFD, skipping the final exon of PIR and first exon of VEGFD. There is also a read-through transcript between CLTRN and ACE2(AC097625.226) that skips the final exon of CLTRN and first exon of ACE2. B) The interacting cluster of contiguous X chromosome genes (not to scale). Circle symbols are blue for protein coding genes, orange for double-elite enhancers, and purple for non-coding RNAs. Grey background indicates overlapping loci on current resolutions. Further, generally weaker interactions have been described and are illustrated for completeness below the core cluster box. Notably however, CA5B is regulated differently to ACE2 (data not shown). and thus impair reactive oxygen species (ROS) scavenging and increase ROS as described in the text. VEGFD consequences are expected to be pulmonary endothelial-specific. Additional cluster genes are not illustrated for clarity.

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Early detection of severe COVID-19 disease patterns define near real-time personalised care, bioseverity in males, and decelerating mortality rates

The unique characteristics of COVID-19 coagulopathy

Pulmonary Angiopathy in Severe COVID-19: Physiologic, Imaging and Hematologic Observations

Vander Heide RS. Pulmonary and Cardiac Pathology in African American patients with COVID-19: an autopsy series from New Orleans

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells

Red blood cell oxidative stress impairs oxygen delivery and induces red blood cell aging

Oxidative stress and microvessel barrier dysfunction

COVID-ARDS Clarified: A Vascular Endotype?

Coagulopathy in COVID-19: Focus on vascular thrombotic events

The angiotensin II-AT1 receptor stimulates reactive oxygen species within the cell nucleus

Novel roles of nuclear angiotensin receptors and signaling mechanisms

Structural determinants of vascular endothelial growth factor-D receptor binding and specificity

Long-Term effect of sirolimus on serum vascular endothelial growth factor D levels in patients with lymphangioleiomyomatosis

Distinct characteristics of VEGF-D and VEGF-C to predict mortality in patients with suspected or known coronary artery